IN2015DN01018A - - Google Patents
Download PDFInfo
- Publication number
- IN2015DN01018A IN2015DN01018A IN1018DEN2015A IN2015DN01018A IN 2015DN01018 A IN2015DN01018 A IN 2015DN01018A IN 1018DEN2015 A IN1018DEN2015 A IN 1018DEN2015A IN 2015DN01018 A IN2015DN01018 A IN 2015DN01018A
- Authority
- IN
- India
- Prior art keywords
- acetoxy
- propoxy
- diphenyl
- alkyl
- methyl
- Prior art date
Links
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 abstract 2
- -1 piperidinium halides Chemical class 0.000 abstract 2
- 229940121683 Acetylcholine receptor antagonist Drugs 0.000 abstract 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 abstract 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/54—Sulfur atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261681415P | 2012-08-09 | 2012-08-09 | |
| PCT/US2013/052626 WO2014025569A1 (en) | 2012-08-09 | 2013-07-30 | Piperidinium quaternary salts |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN01018A true IN2015DN01018A (OSRAM) | 2015-06-26 |
Family
ID=50068488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1018DEN2015 IN2015DN01018A (OSRAM) | 2012-08-09 | 2013-07-30 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9896416B2 (OSRAM) |
| EP (1) | EP2882711B1 (OSRAM) |
| JP (1) | JP6345665B2 (OSRAM) |
| KR (2) | KR102240999B1 (OSRAM) |
| CN (2) | CN108658842A (OSRAM) |
| AU (1) | AU2013300009B2 (OSRAM) |
| BR (1) | BR112015002832B1 (OSRAM) |
| CA (1) | CA2881182C (OSRAM) |
| EA (1) | EA029678B9 (OSRAM) |
| HK (1) | HK1211572A1 (OSRAM) |
| IL (1) | IL236996A0 (OSRAM) |
| IN (1) | IN2015DN01018A (OSRAM) |
| MX (1) | MX356386B (OSRAM) |
| WO (1) | WO2014025569A1 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2978201A1 (en) | 2015-03-06 | 2016-09-15 | Chase Pharmaceuticals Corporation | Use of oxybutynin transdermal formulations to reduce side effects associated with muscarinic agonists |
| CA2992731A1 (en) * | 2015-07-20 | 2017-01-26 | Chase Pharmaceuticals Corporation | Muscarinic combination of a selective m2-antagonist and a peripheral non-selective antagonist for treating hypocholinergic disorders |
| EP3864810B1 (en) | 2019-08-22 | 2023-12-20 | Ofinno, LLC | Policy control for multiple accesses |
| CN117018194A (zh) * | 2023-07-26 | 2023-11-10 | 同济大学 | 毒蕈碱型受体5型受体拮抗剂的用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD106643A1 (OSRAM) * | 1973-07-12 | 1974-06-20 | ||
| CN1285348A (zh) | 1999-08-20 | 2001-02-28 | 广东康美药业股份有限公司 | 盐酸丙哌维林合成工艺 |
| DE10129832A1 (de) * | 2001-06-17 | 2003-07-10 | Berolina Drug Dev Ab Svedala | Deuterierte N- und alpha-substituierte Diphenylalkoxyessigsäureaminoalkylester sowie diese Verbindungen enthaltende Arzneimittel |
| CA2384922C (en) * | 2002-05-03 | 2008-09-02 | Purepharm Inc. | Topical glycopyrrolate product for the reduction of sweating |
| KR100510788B1 (ko) | 2003-07-22 | 2005-08-26 | 동방에프티엘 주식회사 | 프로필벤질릭산 에스터로부터 염산 프로피베린의 제조방법 |
| KR100500760B1 (ko) | 2003-07-22 | 2005-07-14 | 동방에프티엘 주식회사 | 염산 프로피베린의 제조방법 |
| ES2413011T3 (es) * | 2004-02-06 | 2013-07-15 | Meda Pharma Gmbh & Co. Kg | Combinación de anticolinérgicos y glucocorticoides para el tratamiento a largo plazo de asma y EPOC |
| US8548786B2 (en) * | 2005-08-12 | 2013-10-01 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Neuronal avalanche assay |
| CN1951938A (zh) * | 2005-10-21 | 2007-04-25 | 刘丽娅 | 戊乙奎醚季铵盐及其衍生物 |
| SE0600876L (sv) | 2006-04-20 | 2007-10-21 | Sandvik Intellectual Property | Verktyg och skär för spånavskiljande bearbetning med primära och sekundära ingreppsmedel med rotationssymmetrisk form |
| CN101490003A (zh) * | 2006-04-24 | 2009-07-22 | 阿斯利康(瑞典)有限公司 | 具有毒蕈碱m3受体拮抗剂活性、用于治疗入慢性支气管阻塞、哮喘和膀胱过动的新型环状氨基醇的取代烷基酯类化合物 |
| EP2013172A4 (en) * | 2006-04-24 | 2010-08-04 | Astrazeneca Ab | NEW ALKYLESTERS FROM CYCLIC AMINO ALCOHOLS WITH MUSCARIN M3 RECEPTORANTAGONOSTIC ACTIVITY FOR THE TREATMENT OF CHRONIC BRONCHIA SUPPRESSION, ASTHMA OR OVERACTIVE HARNBASE |
| EP2470504B1 (en) * | 2010-03-15 | 2013-10-16 | Ramesha Andagar Ramakrishna | Synthesis of propiverine hydrochloride |
| KR101149821B1 (ko) | 2010-04-05 | 2012-05-24 | 하나제약 주식회사 | 디페닐아세테이트 유도체의 새로운 제조방법 |
| CN102218063B (zh) | 2011-04-12 | 2013-03-13 | 贵州神奇制药有限公司 | 盐酸丙哌维林药物的制备方法和产品及其检测方法 |
| KR20200065113A (ko) * | 2012-09-05 | 2020-06-08 | 체이스 파마슈티칼스 코포레이션 | 항콜린 신경보호 조성물 및 그 방법 |
-
2013
- 2013-07-30 US US14/419,381 patent/US9896416B2/en active Active
- 2013-07-30 EP EP13827594.6A patent/EP2882711B1/en active Active
- 2013-07-30 AU AU2013300009A patent/AU2013300009B2/en not_active Ceased
- 2013-07-30 WO PCT/US2013/052626 patent/WO2014025569A1/en not_active Ceased
- 2013-07-30 IN IN1018DEN2015 patent/IN2015DN01018A/en unknown
- 2013-07-30 EA EA201500209A patent/EA029678B9/ru unknown
- 2013-07-30 CN CN201810664740.3A patent/CN108658842A/zh active Pending
- 2013-07-30 HK HK15112219.3A patent/HK1211572A1/xx unknown
- 2013-07-30 CN CN201380042085.3A patent/CN104603108A/zh active Pending
- 2013-07-30 CA CA2881182A patent/CA2881182C/en active Active
- 2013-07-30 BR BR112015002832-2A patent/BR112015002832B1/pt not_active IP Right Cessation
- 2013-07-30 KR KR1020207005139A patent/KR102240999B1/ko not_active Expired - Fee Related
- 2013-07-30 JP JP2015526567A patent/JP6345665B2/ja not_active Expired - Fee Related
- 2013-07-30 MX MX2015001769A patent/MX356386B/es active IP Right Grant
- 2013-07-30 KR KR20157006047A patent/KR20150040355A/ko not_active Ceased
-
2015
- 2015-01-29 IL IL236996A patent/IL236996A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2882711A4 (en) | 2016-02-10 |
| BR112015002832B1 (pt) | 2022-08-16 |
| CN104603108A (zh) | 2015-05-06 |
| HK1211572A1 (en) | 2016-05-27 |
| CA2881182A1 (en) | 2014-02-13 |
| MX356386B (es) | 2018-05-28 |
| CN108658842A (zh) | 2018-10-16 |
| CA2881182C (en) | 2021-01-26 |
| EA029678B1 (ru) | 2018-04-30 |
| EP2882711B1 (en) | 2017-10-25 |
| JP2015524469A (ja) | 2015-08-24 |
| EP2882711A1 (en) | 2015-06-17 |
| WO2014025569A1 (en) | 2014-02-13 |
| KR20150040355A (ko) | 2015-04-14 |
| KR20200022522A (ko) | 2020-03-03 |
| AU2013300009B2 (en) | 2017-06-15 |
| AU2013300009A1 (en) | 2015-02-26 |
| JP6345665B2 (ja) | 2018-06-20 |
| BR112015002832A2 (OSRAM) | 2017-07-04 |
| US20150203452A1 (en) | 2015-07-23 |
| EA201500209A1 (ru) | 2015-05-29 |
| KR102240999B1 (ko) | 2021-04-15 |
| EA029678B9 (ru) | 2018-07-31 |
| US9896416B2 (en) | 2018-02-20 |
| MX2015001769A (es) | 2015-05-08 |
| IL236996A0 (en) | 2015-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201290984A1 (ru) | Гелеобразные фармацевтические композиции, препятствующие злоупотреблению | |
| PH12014502095A1 (en) | Estrogen receptor modulators and uses thereof | |
| IL235767A (en) | Preserved pyrolidines, pharmaceuticals containing them and their uses | |
| EP4249055A3 (en) | Tofacitinib oral sustained release dosage forms | |
| MX2015008069A (es) | Conjunto de envasado para dispositivos de administracion de farmacos. | |
| IL236057B (en) | History of 4,2,1-triazine-6-carboxamide and pharmaceutical preparations containing them | |
| IN2015DN03984A (OSRAM) | ||
| EA201201202A1 (ru) | Пероральная фармацевтическая композиция, содержащая этексилат дабигатрана | |
| GEP201706739B (en) | Compositions comprising vortioxetine and donepezil | |
| PH12014502856A1 (en) | Solid pharmaceutical preparation containing levothyroxine | |
| MX2016008369A (es) | Composicion farmaceutica que incluye palonosetron. | |
| PH12015501115B1 (en) | Learning and memory improver | |
| MD20150053A2 (ro) | Produs de comicronizare cu conţinut de acetat de ulipristal | |
| MY183068A (en) | Pharmaceutical formulation comprising antibody | |
| IN2015DN01018A (OSRAM) | ||
| IL246298A0 (en) | History of piperidine, their preparation and pharmaceutical preparations containing them | |
| PH12015501377A1 (en) | Solid unit with high fexofenadine content and process for the preparation thereof | |
| IN2015DN02999A (OSRAM) | ||
| WO2014115169A3 (en) | Crizotinib solid dispersion | |
| WO2017004172A8 (en) | Total synthesis of shishijimicin a and analogs thereof | |
| WO2014133746A3 (en) | Oral care compositions | |
| WO2014122671A3 (en) | Solid oral compositions of saxagliptin | |
| MX352596B (es) | Composicion farmaceutica que comprende (1r,4r)-6´-fluoro-n,n-dimet il-4-fenil-4´,9´-dihidro-3´h-espiro[ciclohexan-1,1´-piran-[3,4,b] indol]-4-amina y paracetamol o propacetamol. | |
| IN2013MU02015A (OSRAM) | ||
| 宋双双 | Potentials of proniosomes for improving the oral bioavailability of poorly water-soluble drugs |